Showing results (151-160 of 170) with videos related to
Sort By:
Pageof 17
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.Journal of the American Academy of Dermatology|April 5, 2023
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areataCheng Zhou, Xiumin Yang, Bin Yang, et al.JAMA Dermatology|August 9, 2013
Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaireDeshan F Sebaratnam, Anna Marie Hanna, Shien-ning Chee, et al.International Journal of Dermatology|January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studiesPeter Foley, Michael Freeman, Alan Menter, et al.Journal of Cutaneous Medicine and Surgery|April 14, 2017
Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDTPiergiacomo Calzavara-Pinton, Merete Hædersdal, Kirk Barber, et al.Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.Dermatology and Therapy|February 14, 2025
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of EfficacyJonathan I Silverberg, Thomas Bieber, Amy S Paller, et al.Multiple Sclerosis and Related Disorders|December 9, 2022
Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosisYuan-Ting Chang, Patrick K A Kearns, Alan Carson, et al.The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.The Journal of Investigative Dermatology|April 19, 2026
The role of biosimilars in enhancing global access to psoriasis treatmentYasmina Behlock, Sean P Gavan, Thomas Graier, et al.Pageof 17